Stanley T. Crooke

32.4k total citations · 10 hit papers
415 papers, 25.7k citations indexed

About

Stanley T. Crooke is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Stanley T. Crooke has authored 415 papers receiving a total of 25.7k indexed citations (citations by other indexed papers that have themselves been cited), including 302 papers in Molecular Biology, 64 papers in Oncology and 41 papers in Organic Chemistry. Recurrent topics in Stanley T. Crooke's work include DNA and Nucleic Acid Chemistry (111 papers), RNA Interference and Gene Delivery (66 papers) and Advanced biosensing and bioanalysis techniques (63 papers). Stanley T. Crooke is often cited by papers focused on DNA and Nucleic Acid Chemistry (111 papers), RNA Interference and Gene Delivery (66 papers) and Advanced biosensing and bioanalysis techniques (63 papers). Stanley T. Crooke collaborates with scholars based in United States, United Kingdom and Germany. Stanley T. Crooke's co-authors include Xue‐hai Liang, C. Frank Bennett, Timothy A. Vickers, Brenda F. Baker, Christopher K. Mirabelli, Walt F. Lima, Archie W. Prestayko, Rosanne M. Crooke, Seymour Mong and Hong Sun and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Stanley T. Crooke

411 papers receiving 24.4k citations

Hit Papers

Mipomersen, an apolipopro... 1979 2026 1994 2010 2010 2018 1980 2016 1993 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
    2010 692 citations Stanley T. Crooke et al. profile →
  2. RNA-Targeted Therapeutics
    2018 612 citations Stanley T. Crooke, C. Frank Bennett et al. profile →
  3. Cisplatin : current status and new developments
    1980 608 citations Archie W. Prestayko, Stanley T. Crooke et al. Academic Press eBooks profile →
  4. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
    2016 544 citations Richard S. Geary, Steven G. Hughes et al. profile →
  5. Antisense Research and Applications
    1993 524 citations Stanley T. Crooke et al. profile →
  6. Antisense technology: an overview and prospectus
    2021 469 citations Stanley T. Crooke, Brenda F. Baker et al. profile →
  7. Cellular uptake and trafficking of antisense oligonucleotides
    2017 446 citations Stanley T. Crooke, Timothy A. Vickers et al. profile →
  8. Cisplatin (cis-diamminedichloroplatinum II)
    1979 337 citations Archie W. Prestayko, Stanley T. Crooke et al. profile →
  9. Phosphorothioate modified oligonucleotide–protein interactions
    2020 232 citations Stanley T. Crooke, Timothy A. Vickers et al. profile →
  10. Antisense technology: A review
    2021 217 citations Stanley T. Crooke, Xue‐hai Liang et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanley T. Crooke United States 83 17.8k 4.0k 2.4k 2.3k 2.2k 415 25.7k
Nancy A. Thornberry United States 58 18.3k 1.0× 4.5k 1.1× 2.2k 0.9× 1.3k 0.6× 1.6k 0.7× 110 26.3k
Doriano Fabbro Switzerland 74 12.4k 0.7× 3.7k 0.9× 1.4k 0.6× 1.8k 0.8× 831 0.4× 223 20.3k
Alexander Levitzki Israel 74 14.3k 0.8× 5.9k 1.5× 1.8k 0.7× 1.7k 0.8× 1.0k 0.5× 328 22.3k
Garth Powis United States 79 14.4k 0.8× 3.7k 0.9× 3.9k 1.6× 2.4k 1.1× 897 0.4× 388 22.2k
Peter J. Parker United Kingdom 95 25.3k 1.4× 3.9k 1.0× 2.0k 0.8× 762 0.3× 1.5k 0.7× 406 33.7k
Patrick J. Casey United States 74 14.8k 0.8× 3.4k 0.8× 1.4k 0.6× 1.0k 0.4× 1.4k 0.6× 247 19.3k
Takashi Tsuruo Japan 89 16.6k 0.9× 12.4k 3.1× 2.8k 1.2× 1.7k 0.7× 1.9k 0.9× 446 27.7k
Harvey R. Herschman United States 81 12.5k 0.7× 3.7k 0.9× 2.7k 1.1× 912 0.4× 1.3k 0.6× 330 25.2k
Sue Goo Rhee United States 104 31.0k 1.7× 2.5k 0.6× 1.9k 0.8× 1.0k 0.5× 1.7k 0.8× 244 41.4k
Thomas C. Hamilton United States 65 8.4k 0.5× 4.6k 1.2× 1.7k 0.7× 955 0.4× 771 0.4× 188 14.4k

Countries citing papers authored by Stanley T. Crooke

Since Specialization
Citations

This map shows the geographic impact of Stanley T. Crooke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley T. Crooke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley T. Crooke more than expected).

Fields of papers citing papers by Stanley T. Crooke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley T. Crooke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley T. Crooke. The network helps show where Stanley T. Crooke may publish in the future.

Co-authorship network of co-authors of Stanley T. Crooke

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley T. Crooke. A scholar is included among the top collaborators of Stanley T. Crooke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley T. Crooke. Stanley T. Crooke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crooke, Stanley T.. (2025). Addressing the Needs of Nano-Rare Patients. Nucleic Acid Therapeutics. 35(2). 51–54. 1 indexed citations
2.
Ziegler, Alban, Joanne Carroll, Jennifer Bain, et al.. (2024). Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder. Nature Medicine. 30(10). 2782–2786. 14 indexed citations
3.
Crooke, Stanley T., et al.. (2023). Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response. Nucleic Acid Therapeutics. 33(2). 95–107. 10 indexed citations
4.
Zhang, Lingdi, Xue‐hai Liang, Cheryl Li De Hoyos, et al.. (2022). The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2′- O -Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs. Nucleic Acid Therapeutics. 32(5). 401–411. 11 indexed citations
5.
Zhang, Lingdi, et al.. (2022). NAT10 and DDX21 Proteins Interact with RNase H1 and Affect the Performance of Phosphorothioate Oligonucleotides. Nucleic Acid Therapeutics. 32(4). 280–299. 6 indexed citations
6.
Zhao, Jing, et al.. (2022). SIDT2 Inhibits Phosphorothioate Antisense Oligonucleotide Activity by Regulating Cellular Localization of Lysosomes. Nucleic Acid Therapeutics. 33(2). 108–116. 2 indexed citations
7.
Liang, Xue‐hai, Joshua G Nichols, Chih‐Wei Hsu, & Stanley T. Crooke. (2021). Hsc70 Facilitates Mannose-6-Phosphate Receptor-Mediated Intracellular Trafficking and Enhances Endosomal Release of Phosphorothioate-Modified Antisense Oligonucleotides. Nucleic Acid Therapeutics. 31(4). 284–297. 6 indexed citations
8.
Crooke, Stanley T., Xue‐hai Liang, Brenda F. Baker, & Rosanne M. Crooke. (2021). Antisense technology: A review. Journal of Biological Chemistry. 296. 100416–100416. 217 indexed citations breakdown →
9.
Wang, Shiyu, Nickolas Allen, Thazha P. Prakash, Xue‐hai Liang, & Stanley T. Crooke. (2019). Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells. Nucleic Acid Therapeutics. 29(5). 245–255. 51 indexed citations
10.
Wang, Ying, Wen Shen, Xue‐hai Liang, & Stanley T. Crooke. (2019). Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly. Nucleic Acid Therapeutics. 29(6). 343–358. 10 indexed citations
11.
Crooke, Stanley T., Brenda F. Baker, Nguyen C. Pham, et al.. (2017). The Effects of 2′- O -Methoxyethyl Oligonucleotides on Renal Function in Humans. Nucleic Acid Therapeutics. 28(1). 10–22. 53 indexed citations
12.
Crooke, Stanley T.. (2000). Progress in antisense technology: The end of the beginning. Methods in enzymology on CD-ROM/Methods in enzymology. 313. 3–45. 130 indexed citations
13.
Wu, Hongjiang, et al.. (1998). Molecular Cloning and Expression of cDNA for Human RNase H. Antisense and Nucleic Acid Drug Development. 8(1). 53–61. 46 indexed citations
14.
Bennett, C. Frank, et al.. (1987). Phosphorylation of PI-specific phospholipase C by protein kinase C in vivo. Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States). 1 indexed citations
15.
Cook, M. N., et al.. (1986). Characterization of arachidonate 5-lipoxygenase and leukotriene A4 synthetase from RBL-1 cells. 45(6). 1935. 1 indexed citations
16.
Prestayko, Archie W., et al.. (1980). Cisplatin : current status and new developments. Academic Press eBooks. 608 indexed citations breakdown →
17.
Carter, Stephen K., et al.. (1978). Bleomycin : current status and new developments. Academic Press eBooks. 86 indexed citations
18.
Crooke, Stanley T.. (1977). A review of carminomycin-a new anthracycline developed in the USSR.. PubMed. 8(5). 295–316. 26 indexed citations
19.
Crooke, Stanley T. & William T. Bradner. (1976). Bleomycin, a review.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 7(5). 333–428. 181 indexed citations
20.
Crooke, Stanley T., et al.. (1975). Biochemical effects of bleomycin A2 on Novikoff hepatoma ascites cells.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 7(2). 177–90. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy A. Thornberry Breakdown of academic impact, for papers by Doriano Fabbro Breakdown of academic impact, for papers by Alexander Levitzki Breakdown of academic impact, for papers by Garth Powis Breakdown of academic impact, for papers by Peter J. Parker Breakdown of academic impact, for papers by Patrick J. Casey Breakdown of academic impact, for papers by Takashi Tsuruo Breakdown of academic impact, for papers by Harvey R. Herschman Breakdown of academic impact, for papers by Sue Goo Rhee Breakdown of academic impact, for papers by Thomas C. Hamilton
Rankless by CCL
2026